Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

IdeNtifying reSponse defIninG mecHanisms for biological TherapieS in SevereAsthma (INSIGHTS ); assessing the role of CD4-CTLs

Award Number: R01HL177289
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

IdeNtifying reSponse defIninG mecHanisms for biological TherapieS in SevereAsthma (INSIGHTS ); assessing the role of CD4-CTLs - PROJECT SUMMARY Severe asthma, characterized by persistent airway inflammation and corticosteroid resistance, afflicts millions of Americans with limited therapeutic options. Clinicians currently rely on Type 2 immune biomarkers for patient classification (T2HIGH vs. T2LOW) and treatment decisions. However, real-world studies revealed the over- representation of the T2HIGH endotype in severe asthma and those treated with anti-T2 biologic therapies exhibit contrasting responses, challenging the efficacy of this T2 dichotomy and highlighting the need to explore alternative pathophysiological drivers. Our single-cell transcriptome analysis of T cells from inflamed airways in severe asthmatics identified a novel subset of pathogenic airway tissue resident cytotoxic CD4+ T cells (CD4-CTLs). Despite biologic treatment, CD4- CTLs remained activated, producing inflammatory molecules. Cell proportions analysis linked CD4-CTLs to asthma severity and lung function impairment, particularly in males with late-onset asthma. The study strongly supports CD4-CTLs' significant contribution to airway inflammation, potentially hindering T2-biologic response. Led by a multidisciplinary team of experts in clinical asthma, and immuno-genomics, Drs. Kurukulaaratchy and Seumois, our INSIGHTS study aims to assess the impact of CD4-CTLs on severe asthma pathogenesis and T2- biologics response at a larger scale. AIM 1: We will analyze airway CD4-CTLs from blood and sputum samples collected from 160 severe asthmatic patients before, and 12- and 24- months after initiating T2-biologic therapy. We will evaluate the impact of CD4- CTLs on T2-biologics response through extensive clinical analysis. Samples will be collected by three clinical centers [University of Southampton, UK; University of Michigan, Ann Arbor, US, and University of California, San Diego, US] establishing the clinical significance of CD4-CTL as a new player in asthma pathogenesis. AIM 2: With the planned collection of samples, we will generate up to 1 million single-CD4-CTL cell transcriptomes allowing us to comprehensively decipher the pathogenic cellular and molecular features of CD4- CTLs in asthma severity and response to T2-biologics, as well as investigate their function through TCR- reactivity and interactions with structural cells analysis. In summary, this unique translational proposal aims to unveil mechanisms causing a lack or loss of response to T2-biologics in severe asthma, focusing on CD4-CTLs. Findings could establish CD4-CTLs as a better predictor for patient stratification, leading to novel therapies for unmet patient needs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,436,586 )
2025	2025	SAN DIEGO BIOMEDICAL RESEARCH INSTITUTE	3525 JOHN HOPKINS CT STE 200	SAN DIEGO	CA	92121	SAN DIEGO	USA	Lung Diseases Research	000	1	9/22/2025	NEW	$1,436,586
														Subtotal = $1,436,586

Grand Total All Awards = $1,436,586

Top

All Categories

About

Search

Reports

Data Submission

Award Information

IdeNtifying reSponse defIninG mecHanisms for biological TherapieS in SevereAsthma (INSIGHTS ); assessing the role of CD4-CTLs

Award Number: R01HL177289

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer